Peter Campochiaro, M.D., SAB member 

Peter Campochiaro, M.D. is the George S. & Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine. Dr. Campochiaro has strong expertise with retinal diseases including animal models for NVAMD and significant experience with clinical trials testing NVAMD agents such as Lucentis (Genentech/Roche) and Eylea (Regeneron). Dr. Campochiaro has published over 300 scientific papers in these research areas. He serves as a Member of Scientific Advisory Board of CoMentis, Inc. (alternate name Athenagen Inc) and as a Member of the Scientific Advisory Board of Potentia Pharmaceuticals, Inc. Dr. Campochiaro served as a Member of Scientific Advisory Board of Eyegate Pharmaceuticals, Inc.


henry_bremHenry Brem, M.D., SAB member 

Henry Brem, M.D. is the Harvey Cushing Professor of Neurosurgery, Oncology, Ophthalmology, and Biomedical Engineering, and Director of Neurosurgery at Johns Hopkins University School of Medicine and is a member of the Institute of Medicine of the National Academy of Sciences. Dr. Brem received his undergraduate degree from New York University, his medical degree from Harvard, and trained in neurosurgery at Columbia. He has built one of the largest brain tumor research and treatment centers in the world. He reinstituted the Hunterian Neurosurgery Laboratory (originally founded by Cushing) and has trained numerous researchers who have changed the fields of intraoperative imaging, angiogenesis, immunotherapy, and controlled release polymers for drug delivery to the brain. Dr. Brem’s work led to the FDA’s approval of the first image guidance computer system for intraoperative localization of tumors. Furthermore, he has changed the surgical armamentarium against brain tumors by inventing and developing Gliadel® wafers to intraoperatively deliver chemotherapy to brain tumors. He developed new classes of polymers for drug delivery that are custom synthesized for the agent being developed and led the clinical trials demonstrating their safety and efficacy. He has also explored the role of antiangiogenesis agents in synergy with chemotherapeutic agents. Brem’s leadership and his team at Johns Hopkins have been recognized by being named the #1 neurosurgery program in the U.S. by US News & World Report. Dr. Brem has been a member of the following Scientific Advisory Boards: Northwest Biotherapeutics, BrainsGate, CytoDome, Accelerate Brain Cancer Cure, PureTech Ventures, and Guilford Pharmaceuticals among others and he has been on the Board of Directors of Alseres Pharmaceuticals, Inc. and Focal, Inc. He is also a member of Editorial Boards of Neurosurgery and World Neurosurgery. Dr. Brem has published over 250 papers and given more than 400 invited talks.